Ascrinvacumab
Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a Kd value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC) [1].
Product Specifications
CAS Number
[1463459-96-2]
Product Name Alternative
Anti-ACVRL1 / ALK-1 Reference Antibody (ascrinvacumab) ; PF-03446962; GT-90001C
UNSPSC
12352203
Target
Anaplastic lymphoma kinase (ALK)
Type
Inhibitory Antibodies
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ascrinvacumab.html
Purity
97.45
Solubility
10 mM in DMSO
Smiles
[Ascrinvacumab]
Molecular Weight
(144.08 kDa)
References & Citations
[1]van Meeteren LA, et al. Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9) -induced ALK1 signaling and interferes with endothelial cell sprouting. J Biol Chem. 2012 May 25;287 (22) :18551-61.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
123355 100 µg
ANXA2 (Annexin A2, Annexin II, Annexin-2, Calpactin I Heavy Chain, Calpactin-1 Heavy Chain, Chromobindin-8, Lipocortin II, Placental Anticoagulant Protein IV, PAP-IV, Protein I, p36, ANX2, ANX2L4, CAL1H, LPC2D)
Ask
View Details 
